The French pharmaceutical giant Sanofi announced large-scale positive results of its anti-COVID vaccine, developed jointly with the British laboratory GSK, after a year of trials and postponements.
“Sanofi and GSK will seek regulatory approval for their COVID-19 vaccine″ in the United States and the European Union (EU), both groups announced in a statement, after trials with thousands of people.
Although the full studies have not yet been published, their results show that the drug helps prevent hospitalization due to the coronavirus.
Additionally, the vaccine would be slightly more than 50% effective for symptomatic COVID.
That’s it “comparable to the efficacy of already available vaccines” highlighted Sanofi, in a context of strong spread of the pandemic due to the omicron variant.
If the vaccine is authorized, that will mean the end of a long journey for both pharmaceutical companies, who hoped to be able to market the drug in mid-2021.
The first difficulties arose with the correct dosage of the vaccine, and then with the difficulties of finding people who had never been infected, so that the tests were reliable.
Sanofi had to abandon its attempts to create a vaccine based on mRNA technology, which has been the basis for rivals Pfizer-BioNTech and Moderna.
Source: Gestion
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
